- Home
- LDTC vs HOTH Comparison
LDTC vs HOTH Comparison
Compare LDTC & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- HOTH
- Stock Information
- Founded
- LDTC 2007
- HOTH 2017
- Country
- LDTC Canada
- HOTH United States
- Employees
- LDTC N/A
- HOTH N/A
- Industry
- LDTC Blank Checks
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- HOTH Health Care
- Exchange
- LDTC Nasdaq
- HOTH Nasdaq
- Market Cap
- LDTC 7.9M
- HOTH 7.6M
- IPO Year
- LDTC N/A
- HOTH 2019
- Fundamental
- Price
- LDTC $0.32
- HOTH $0.82
- Analyst Decision
- LDTC Buy
- HOTH Strong Buy
- Analyst Count
- LDTC 3
- HOTH 4
- Target Price
- LDTC $1.00
- HOTH $4.75
- AVG Volume (30 Days)
- LDTC 157.6K
- HOTH 996.3K
- Earning Date
- LDTC 08-14-2024
- HOTH 11-12-2024
- Dividend Yield
- LDTC N/A
- HOTH N/A
- EPS Growth
- LDTC N/A
- HOTH N/A
- EPS
- LDTC N/A
- HOTH N/A
- Revenue
- LDTC $6,052,694.00
- HOTH N/A
- Revenue This Year
- LDTC N/A
- HOTH N/A
- Revenue Next Year
- LDTC $2.28
- HOTH N/A
- P/E Ratio
- LDTC N/A
- HOTH N/A
- Revenue Growth
- LDTC 2.76
- HOTH N/A
- 52 Week Low
- LDTC $0.22
- HOTH $0.58
- 52 Week High
- LDTC $11.20
- HOTH $1.73
- Technical
- Relative Strength Index (RSI)
- LDTC 59.16
- HOTH 42.93
- Support Level
- LDTC $0.28
- HOTH $0.83
- Resistance Level
- LDTC $0.35
- HOTH $0.90
- Average True Range (ATR)
- LDTC 0.04
- HOTH 0.09
- MACD
- LDTC 0.01
- HOTH -0.01
- Stochastic Oscillator
- LDTC 75.97
- HOTH 10.18
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.